Reta: What the Slang Means and What Research Says About Retatrutide

“Reta” is online shorthand for retatrutide, an investigational triple agonist of the GIP, GLP-1, and glucagon receptors studied in clinical trials for obesity and type 2 diabetes. The term spread through forums and social media as a quick way to write a long drug name — it is slang for the molecule, not a separate product, brand, or approved medicine.

Research-use context. This article explains a piece of online terminology and reviews published research. It is not medical advice, a dosing guide, or a weight-loss protocol. Retatrutide in the One-Peptides catalog is a research reagent (Research Use Only) — not a drug, not for human or veterinary use. The approved incretin medicines named below are separate, prescription-only products.

Where the word “Reta” comes from

Retatrutide is a mouthful. As coverage of next-generation incretin compounds grew — alongside semaglutide (“sema”) and tirzepatide (“tirze”) — communities discussing the research literature compressed the names. “Reta” follows the same pattern: an informal abbreviation that travels well in posts, comments, and search boxes. When someone types “reta” into a search engine, they are almost always looking for retatrutide.

That matters for one practical reason: the slang carries no regulatory meaning. “Reta” is not a drug you can be prescribed, not a supplement, and not a One-Peptides product name. It is a nickname for an investigational compound with phase III topline readouts announced in 2026, not a medicine approved by the FDA or EMA.

What retatrutide actually is

Retatrutide is a synthetic peptide (39 amino acids) engineered to activate three receptors at once:

• GLP-1 receptor — the target of semaglutide; linked in research to appetite signalling and glucose-dependent insulin release.
• GIP receptor — the second target added in tirzepatide; studied for its role in insulin response and lipid handling.
• Glucagon receptor — the third target unique to this class; studied in connection with energy expenditure.

This is why retatrutide is described as a triple agonist, the next step in a clear progression: single-receptor (semaglutide) → dual-receptor (tirzepatide) → triple-receptor (retatrutide). The overview article on this site walks through that family in detail — see the full guide to GLP-1 and incretin peptides.

In reagent catalogs, the same molecule may be described by a catalog name rather than its international nonproprietary name. In our catalog, retatrutide appears as Triple G: retatrutide in the catalog. This is another name for the same compound, alongside the slang term “reta” and the manufacturer’s designation LY3437943.

In a phase 2 obesity trial, the 12 mg group reported a mean body-weight change of −24.2% after 48 weeks, compared with −2.1% in the placebo group (Jastreboff et al., 2023) — a figure reported here as published clinical-trial data, not as an outcome associated with any research reagent or with personal use.

Commonly misspelled as

The name is hard to spell, so search data is full of variants. If you arrived here via any of these, they all refer to retatrutide:

Misspelling	Correct name
ratitrutide, retratitude, retatrutode	retatrutide
tetratutide, reattrutide, retatrutid	retatrutide
“reta peptide”, “reta compound”	retatrutide

Using the correct spelling — retatrutide — will surface the most accurate research literature.

How does retatrutide differ from semaglutide?

Retatrutide activates the GIP, GLP-1 and glucagon receptors, whereas semaglutide acts only on the GLP-1 receptor.

A frequent point of confusion: people assume “reta” is interchangeable with Ozempic, Wegovy, Mounjaro, or Zepbound. It is not.

• Ozempic / Wegovy are brand names for semaglutide (single agonist), an approved medicine.
• Mounjaro / Zepbound are brand names for tirzepatide (dual agonist), an approved medicine.
• Retatrutide (“reta”) is a triple agonist still in clinical trials — no approved brand name exists.

There is also a regulatory distinction that sits underneath all of this. The approved products above are prescription medicines studied and authorised for human use. A research reagent sold under Research Use Only terms is a different category entirely: a laboratory material, not a treatment. For how that line is drawn, see research-grade reagents versus approved medicines.

Earlier generations of this family are listed in the catalog as research reagents: Semaglutide 2 mg represents GLP-1 monoagonism, while Tirzepatide (GLP-1+GIP) 5 mg represents the dual-receptor variant. Both entries have RUO status: they are reagents for laboratory applications, not equivalents of registered medicinal products with the same international nonproprietary names. Semaglutide 2 mg is currently out of stock; its link provides the product specification.

Frequently asked questions

What does “reta” mean?

It is informal shorthand for retatrutide, an investigational triple-receptor agonist (GIP/GLP-1/glucagon). It is slang for the molecule, not a brand or approved product.

Is retatrutide the same as Mounjaro?

No. Mounjaro is a brand name for tirzepatide, a dual agonist and an approved medicine. Retatrutide is an investigational triple agonist with phase III topline results announced in 2026, but it has no approved brand name.

Reta vs. tirzepatide — what’s the difference?

Tirzepatide activates two receptors (GIP and GLP-1); retatrutide adds a third (glucagon). In clinical research the triple agonist has been studied at higher reported weight-reduction figures, but it remains investigational while tirzepatide is approved.

Is “reta” something I can buy as a supplement?

No. Retatrutide is not a dietary supplement and not an approved drug. In the One-Peptides catalog it exists only as a research reagent (Research Use Only) for laboratory study.

Is retatrutide an approved medicine?

Retatrutide is not an approved medicine in any jurisdiction and remains an investigational molecule supplied only as a Research Use Only reagent.

“Reta” is just shorthand for retatrutide — a triple-receptor agonist in clinical development, not an approved medicine and not a supplement. The research is genuinely interesting; the terminology is casual. If you want the underlying science, start with the retatrutide research overview and the incretin peptide guide.

Within the metabolic modulators category, retatrutide belongs to the latest generation of incretin compounds.

References

1. Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
2. Coskun T, Urva S, Roell WC, et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss

 

Written by Bartosz Bartczak — One-Peptides. Medically and pharmacologically reviewed by Aneta Kropicka, MPharm (Master of Pharmacy). Last reviewed: 2026-06-14.